[go: up one dir, main page]

NO20054945L - Orale formulering av cladribin - Google Patents

Orale formulering av cladribin

Info

Publication number
NO20054945L
NO20054945L NO20054945A NO20054945A NO20054945L NO 20054945 L NO20054945 L NO 20054945L NO 20054945 A NO20054945 A NO 20054945A NO 20054945 A NO20054945 A NO 20054945A NO 20054945 L NO20054945 L NO 20054945L
Authority
NO
Norway
Prior art keywords
cladribine
oral formulation
oral
formulation
cyclodextrin
Prior art date
Application number
NO20054945A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054945D0 (no
Inventor
Nicholas S Bodor
Yogesh Dandiker
Original Assignee
Ivax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Corp filed Critical Ivax Corp
Publication of NO20054945D0 publication Critical patent/NO20054945D0/no
Publication of NO20054945L publication Critical patent/NO20054945L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
NO20054945A 2003-03-28 2005-10-25 Orale formulering av cladribin NO20054945L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45892203P 2003-03-28 2003-03-28
US48475603P 2003-07-02 2003-07-02
US54124704P 2004-02-04 2004-02-04
PCT/US2004/009387 WO2004087101A2 (fr) 2003-03-28 2004-03-26 Formulations de cladribine a administration par voie orale

Publications (2)

Publication Number Publication Date
NO20054945D0 NO20054945D0 (no) 2005-10-25
NO20054945L true NO20054945L (no) 2005-11-24

Family

ID=33135982

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054945A NO20054945L (no) 2003-03-28 2005-10-25 Orale formulering av cladribin

Country Status (27)

Country Link
US (2) US7888328B2 (fr)
EP (1) EP1608344B1 (fr)
JP (1) JP5256611B2 (fr)
KR (1) KR101129816B1 (fr)
AT (1) ATE476177T1 (fr)
AU (2) AU2004226437B2 (fr)
BR (2) BR122018068797B1 (fr)
CA (1) CA2520523C (fr)
CY (2) CY1112591T1 (fr)
DE (1) DE602004028448D1 (fr)
DK (2) DK2272503T3 (fr)
EA (1) EA009944B1 (fr)
ES (1) ES2409884T3 (fr)
HR (1) HRP20050925A2 (fr)
HU (1) HUS1800013I1 (fr)
IL (1) IL213853A0 (fr)
IS (1) IS2799B (fr)
LT (1) LTC1608344I2 (fr)
LU (1) LUC00065I2 (fr)
ME (1) ME00249B (fr)
MX (1) MXPA05010329A (fr)
NO (1) NO20054945L (fr)
PL (1) PL1608344T3 (fr)
PT (1) PT1608344E (fr)
RS (2) RS51115B (fr)
SG (1) SG175450A1 (fr)
WO (1) WO2004087101A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060011943A (ko) * 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
BRPI0517132B8 (pt) 2004-12-22 2021-05-25 Laboratoires Serono S A uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla
CA2649810A1 (fr) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Regime a base de cladribine pour traiter la sclerose en plaques
EP2343074A1 (fr) 2009-12-23 2011-07-13 Merck Serono S.A. Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
WO2012097867A1 (fr) 2011-01-18 2012-07-26 Synthon Bv Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
US10849919B2 (en) 2017-11-24 2020-12-01 Merck Patent Gmbh Cladribine regimen for treating progressive forms of multiple sclerosis
EP3628310A1 (fr) 2018-09-25 2020-04-01 Synbias Pharma AG Composition pharmaceutique comprenant des dispersions solides de cladribine amorphe et support hydrosoluble pharmaceutiquement acceptable
RU2748311C1 (ru) * 2020-01-29 2021-05-21 Общество с ограниченной ответственностью "ФармЭко" Фармацевтическая композиция, содержащая твердые дисперсии аморфного кладрибина и фармацевтически приемлемый водорастворимый носитель
WO2022053608A1 (fr) 2020-09-10 2022-03-17 Merck Patent Gmbh Nouveau régime de traitement pour le traitement de troubles auto-immuns
CA3209648A1 (fr) 2021-03-03 2022-09-09 Ursula BOSCHERT SHAFAATIAN Procedes de traitement ameliores utilisant des dmd pour le traitement de maladies auto-immunes, et biomarqueur pour predire et/ou optimiser lesdits procedes de traitement
RU2758436C1 (ru) * 2021-04-05 2021-10-28 Общество с ограниченной ответственностью «ФармЭко» Способ получения аморфных ко-эвапоратов кладрибина с циклодекстринами
US20240207419A1 (en) * 2021-04-28 2024-06-27 Biophore India Pharmaceuticals Pvt. Ltd. SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD
CA3259422A1 (fr) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Formulation sublinguale de composé anticancéreux destinée à être utilisée dans le traitement de maladies neurodégénératives auto-immunes
WO2025125527A1 (fr) 2023-12-14 2025-06-19 Ares Trading S.A. Régime de cladribine pour le traitement de la myasthénie grave

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
HU181703B (en) 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
DE3372705D1 (en) 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3317064A1 (de) 1983-05-10 1984-11-15 Consortium für elektrochemische Industrie GmbH, 8000 München Verfahren zur herstellung von cyclooctaamylose
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
JP2575460B2 (ja) * 1988-05-12 1997-01-22 東京田辺製薬株式会社 ダナゾール−シクロデキストリン包接化合物
HK1009335A1 (en) 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
JPH07507775A (ja) * 1992-05-19 1995-08-31 ザ スクリップス リサーチ インスティテュート 慢性骨髄性白血病の治療薬としての２−ハロアデニン誘導体の使用
DE4237639A1 (de) * 1992-11-07 1994-05-11 Basf Ag Verfahren zur Herstellung von Polymeren mit NLO-aktiven Seitengruppen und deren Verwendung
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
HUP9900730A3 (en) * 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
JPH10265495A (ja) * 1997-03-25 1998-10-06 Meiji Milk Prod Co Ltd フルオロプロゲステロン誘導体包接化合物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
AU759280C (en) 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
AU3954799A (en) * 1998-05-29 1999-12-20 Janssen Pharmaceutica N.V. Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
US6239118B1 (en) * 1999-10-05 2001-05-29 Richard A. Schatz Method for preventing restenosis using a substituted adenine derivative
US7141555B2 (en) * 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures

Also Published As

Publication number Publication date
CA2520523A1 (fr) 2004-10-14
IS2799B (is) 2012-09-15
AU2010214777A1 (en) 2010-09-23
EP1608344B1 (fr) 2010-08-04
IS8051A (is) 2005-09-28
EA009944B1 (ru) 2008-04-28
CY2018005I1 (el) 2018-06-27
HK1150266A1 (en) 2011-11-18
AU2004226437B2 (en) 2010-06-03
ATE476177T1 (de) 2010-08-15
US8785415B2 (en) 2014-07-22
BRPI0408848B8 (pt) 2021-07-27
HUS1800013I1 (hu) 2018-03-28
AU2004226437A1 (en) 2004-10-14
CA2520523C (fr) 2011-10-11
ME00249B (fr) 2011-05-10
DK2272503T3 (da) 2013-05-21
JP5256611B2 (ja) 2013-08-07
US20110097306A1 (en) 2011-04-28
US7888328B2 (en) 2011-02-15
HRP20050925A2 (en) 2006-08-31
PT1608344E (pt) 2010-09-02
IL213853A0 (en) 2011-07-31
CY2018005I2 (el) 2018-06-27
JP2006521403A (ja) 2006-09-21
HK1089654A1 (en) 2006-12-08
MEP34308A (en) 2011-02-10
BR122018068797B1 (pt) 2021-04-27
SG175450A1 (en) 2011-11-28
LTPA2018502I1 (lt) 2018-03-12
RS20050735A (en) 2008-06-05
MXPA05010329A (es) 2006-05-31
EA200600404A1 (ru) 2006-08-25
LUC00065I2 (fr) 2018-03-28
PL1608344T3 (pl) 2011-01-31
US20070197468A1 (en) 2007-08-23
BRPI0408848A (pt) 2006-04-04
DE602004028448D1 (de) 2010-09-16
BRPI0408848A8 (pt) 2017-12-26
WO2004087101A2 (fr) 2004-10-14
DK1608344T3 (da) 2010-09-06
WO2004087101A3 (fr) 2005-02-03
ES2409884T3 (es) 2013-06-28
EP1608344A2 (fr) 2005-12-28
NO20054945D0 (no) 2005-10-25
LTC1608344I2 (lt) 2019-03-12
RS20050734A (sr) 2008-06-05
BRPI0408848B1 (pt) 2018-11-27
RS51115B (sr) 2010-10-31
AU2010214777B2 (en) 2013-01-31
KR101129816B1 (ko) 2012-03-26
LUC00065I1 (fr) 2018-02-14
CY1112591T1 (el) 2016-02-10
KR20060015487A (ko) 2006-02-17

Similar Documents

Publication Publication Date Title
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
NO20054944L (no) Cladribinformuleringer for forbedret oral og transmuskos administrering
NO20082547L (no) Orale formuleringer omfattende tigecycline
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
EA200802365A1 (ru) Аминометилзамещенные тетрациклиновые соединения
NO20090346L (no) Pyrazolderivater som inhibitorer av cytokrom P450
DK1499590T3 (da) Piperidinderivater som kaliumkanalblokkere
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
NO20063393L (no) Farmasoytiske preparater
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
NO20062878L (no) Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme
NO20090392L (no) Penem promedikamenter
ATE539082T1 (de) Oxazinylisoflavonoidverbindungen, medikamente und anwendungen
NO20060510L (no) Emulgerende systemer inneholdende azetidinderivater
NO20063293L (no) Farmasoytiske forbindelser
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
DK1824565T3 (da) Orale sammensætninger til forebyggelse og reduktion af bakterieadhæsion på orale overflader
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
DK1827496T3 (da) Orale behandlingssammensætninger indeholde et antiadhæsionsmiddel, et antibakterielt middel og en inkompatibel forbindelse
NO20085285L (no) 2-alkosy-3,4,5-tnhydroksyalkylamidbenzazepiner, deres fremstilling og bruk samt preparater inneholdende disse
NO20085267L (no) Derivater av 2-alkoksy -3,4,5-trihydroksy-alkyl amider, fremstilling og anvendelse derav, samt sammensetninger inneholdende samme
EP2272503A3 (fr) Formulation orale de cladribine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application